Curated News
By: NewsRamp Editorial Staff
October 20, 2026
Oncotelic's Saran Saund to Keynote Drug Discovery Summit on AI
TLDR
- Oncotelic's CBO keynotes at the Drug Discovery Summit, showcasing PDAOAI's 29 million abstract index and IP strategy to gain an edge in AI drug discovery.
- Oncotelic's PDAOAI platform organizes AI drug discovery by partitioning complex research into focused investigations and aggregating findings into testable hypotheses.
- Oncotelic's Fastbot and Membot technology aims to make AI-powered research accessible to individual investigators, potentially accelerating treatments for unmet medical needs.
- Saran Saund will explain how dividing research questions into focused investigations and combining findings can lead to testable hypotheses at the Drug Discovery Summit.
Impact - Why it Matters
The integration of AI into drug discovery holds the potential to significantly reduce the time and cost associated with bringing new therapies to market. Oncotelic’s PDAOAI platform, with its extensive indexing of scientific literature, could empower researchers to identify novel drug targets and repurpose existing compounds more efficiently. By making AI-powered research tools accessible to individual investigators, Oncotelic may democratize drug discovery, enabling smaller research teams and academic labs to compete with larger organizations. This could lead to a more diverse pipeline of therapeutic candidates, particularly for rare pediatric cancers and other unmet medical needs. As the industry increasingly relies on data-driven approaches, Oncotelic’s advancements could position it as a key player in the AI-enabled drug discovery space, potentially attracting partnerships and investment. For patients, this means faster access to innovative treatments, while investors may see long-term value in the company’s proprietary technology and strategic vision.
Summary
Oncotelic Therapeutics (OTCQB: OTLC) has announced that Chief Business Officer Saran Saund will deliver the opening keynote on the second day of the 22nd Drug Discovery Strategic Summit, scheduled for Oct. 22, 2026, at 9 a.m. Pacific Time in Millbrae, California. Saund’s presentation will delve into partition and aggregation as an organizing principle for AI-enabled drug discovery, emphasizing how complex research questions can be divided into focused investigations and findings combined to develop testable hypotheses. He will also discuss Oncotelic’s proprietary PDAOAI platform, which indexes approximately 29 million PubMed abstracts, along with the company’s international intellectual property strategy, planned expansion into genetic discovery, and Fastbot/Membot technology designed to make AI-powered research accessible to individual investigators.
Oncotelic Therapeutics, Inc. develops oncology and immunotherapy products, concentrating on cancers with substantial unmet needs and rare pediatric indications. The company also develops the PDAOAI platform to support its drug discovery and development efforts. The keynote appearance underscores Oncotelic’s commitment to leveraging artificial intelligence to streamline and enhance the drug discovery process, potentially accelerating the development of novel therapeutics. The PDAOAI platform’s vast indexing of scientific literature and its planned expansion into genetic discovery signal the company’s ambition to provide powerful, accessible tools for researchers.
For investors and industry observers, the latest news and updates relating to OTLC are available in the company’s newsroom at https://nnw.fm/OTLC. The full press release can be viewed at https://nnw.fm/O1lLk. The announcement was distributed through NetworkNewsWire, a specialized communications platform focused on financial news and content distribution. NetworkNewsWire is part of the Dynamic Brand Portfolio @ IBN, which offers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution via IBN to millions of social media followers, and a full array of tailored corporate communications solutions.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Oncotelic's Saran Saund to Keynote Drug Discovery Summit on AI
